In the early days of biosimilar utilization, the nocebo effect was a clear worry of the biosimilar industry. When patients knew they were receiving a biosimilar rather than a reference product, discontinuation rates and adverse drug events were noticeably higher. On an absolute basis, nocebo rates are not alarmingly high; a 2018 study found reported … Continue reading Mitigating the Biosimilar Nocebo Effect